We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
An Expert Working Group (EWG) of the UK’s Commission on Human Medicines (CHM) has published their report on the use of hormone pregnancy tests (HPTs) and adverse effects relating to pregnancy including possible birth defects.
A group of independent experts will review all evidence provided; we will publish a report of the group’s findings.
New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for longer after stopping HRT than...
Public call for evidence launched relating to the use of hormonal pregnancy tests.
A review of the latest evidence on the risk of thromboembolism advises to consider risk factors and remain vigilant for signs and symptoms. - the risk of blood clots with all low-dose CHCs is small - there is good evidence...
Latest evidence suggests long-term use of combined oral contraceptives or progestogen-only injectable contraceptives is associated with a small increased risk of cervical cancer.
Following extensive changes to the formulation and manufacture of levothyroxine tablets by Teva, the Commission on Human Medicines (CHM) is now reassured that Teva has demonstrated an acceptable level of efficacy and safety to allow their levothyroxine tablets to re-enter...
Medicines or herbal remedies that induce CYP3A4 enzymes reduce blood levels of levonorgestrel, which may reduce emergency contraceptive efficacy.
Increased risk of stroke in older women should be taken into account in prescribing decisions.
Risk of venous thromboembolism (VTE) for drospirenone-containing combined oral contraceptives (COCs), including Yasmin, is higher than for levonorgestrel-containing COCs.
Men who inject anabolic steroids and tanning drugs are at higher risk of HIV and viral hepatitis.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).